Effect of Vitamin D therapy on urinary albumin excretion, renal functions, and plasma renin among patients with diabetic nephropathy: A randomized, double-blind clinical trial

被引:1
作者
Liyanage, P. L. G. C. [1 ]
Lekamwasam, S. [2 ]
Weerarathna, T. P. [2 ]
Liyanage, C. [3 ]
机构
[1] Univ Ruhuna, Dept Pharmacol, Fac Med, Galle, Sri Lanka
[2] Univ Ruhuna, Dept Med, Fac Med, Galle, Sri Lanka
[3] Univ Ruhuna, Nucl Med Unit, Fac Med, Galle, Sri Lanka
关键词
Albuminuria; diabetic nephropathy; renin; Vitamin D; SUPPLEMENTATION; PARICALCITOL; PROTEINURIA; CALCITRIOL;
D O I
10.4103/jpgm.JPGM_598_16
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Despite different management strategies, progression of proteinuria occurs in a sizable category of patients with diabetic nephropathy (DN). Increase in serum renin levels induced by the renin-angiotensin system (RAS) may contribute to this. Vitamin D therapy is found to have an inhibitory effect on the RAS. We aimed to study the effects of Vitamin D therapy on renal functions of patients with DN. Methods: This was a double-blind, randomized, placebo-controlled study. Patients with DN (urinary albumin [UA] > 30 mg/g of creatinine) whose estimated glomerular filtration rate (eGFR) was more than 30 mL/min were selected and their plasma renin, parathyroid hormone, serum Vitamin D, serum calcium, serum creatinine, fasting blood sugar were done as baseline measurements. Subjects were randomized into two groups and treatment group was given Vitamin D, 50000 IU (0.25 ml) intramuscularly (IM) monthly for 6 months; control group received distilled water IM. Investigations were repeated after 6 months of therapy. Results: Of 155 patients invited, 85 were randomly assigned to two groups. After 6 months, mean reduction of UA to creatinine ratio in the treatment and control group was 51.8 mg/g (95% confidence interval [CI]; 66.1--37.5, P = 0.001); 22.4 mg/g (95% CI; -45.7-0.8, P = 0.06), respectively (between group difference P = 0.001). Significant increase in the eGFR observed in the treatment group while eGFR remained unchanged in the control group (P = 0.03 for the between-group difference). Mean reduction in plasma renin in treatment group and control group was 5.85 pg/mL (95% CI; -6.7--4.6) (P < 0.001) and 0.95 pg/mL (95% CI; -1.4--0.14, P = 0.02), respectively. Conclusions: Vitamin D 50000 IU given IM monthly for 6 months reduces urine albumin, serum creatinine, and renin levels in patients with DN.
引用
收藏
页码:10 / 15
页数:6
相关论文
共 16 条
[1]   Antiproteinuric effect of oral paricalcitol in chronic kidney disease [J].
Agarwal, R ;
Acharya, M ;
Tian, J ;
Hippensteel, RL ;
Melnick, JZ ;
Qiu, P ;
Williams, L ;
Batlle, D .
KIDNEY INTERNATIONAL, 2005, 68 (06) :2823-2828
[2]   Vitamin D, Proteinuria, Diabetic Nephropathy, and Progression of CKD [J].
Agarwal, Rajiv .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (09) :1523-1528
[3]   Paricalcitol reduces albuminuria and inflammation in chronic kidney disease - A randomized double-blind pilot trial [J].
Alborzi, Pooneh ;
Patel, Nina A. ;
Peterson, Carla ;
Bills, Jennifer E. ;
Bekele, Dagim M. ;
Bunaye, Zerihun ;
Light, Robert P. ;
Agarwal, Rajiv .
HYPERTENSION, 2008, 52 (02) :249-255
[4]  
[Anonymous], 2003, Am J Kidney Dis, V42, P1
[5]   Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes [J].
Bischoff-Ferrari, Heike A. ;
Giovannucci, Edward ;
Willett, Walter C. ;
Dietrich, Thomas ;
Dawson-Hughes, Bess .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 84 (01) :18-28
[6]   Diabetic nephropathy: Diagnosis, prevention, and treatment [J].
Gross, JL ;
de Azevedo, MJ ;
Silveiro, SP ;
Canani, LH ;
Caramori, ML ;
Zelmanovitz, T .
DIABETES CARE, 2005, 28 (01) :164-176
[7]   Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial [J].
Joergensen, C. ;
Tarnow, L. ;
Goetze, J. P. ;
Rossing, P. .
DIABETIC MEDICINE, 2015, 32 (03) :374-381
[8]   A New Equation to Estimate Glomerular Filtration Rate [J].
Levey, Andrew S. ;
Stevens, Lesley A. ;
Schmid, Christopher H. ;
Zhang, Yaping ;
Castro, Alejandro F., III ;
Feldman, Harold I. ;
Kusek, John W. ;
Eggers, Paul ;
Van Lente, Frederick ;
Greene, Tom ;
Coresh, Josef .
ANNALS OF INTERNAL MEDICINE, 2009, 150 (09) :604-612
[9]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860
[10]  
Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI200215219, 10.1172/JCI0215219]